Our current, more holistic understanding of DMD pathogenesis, especially with more recent knowledge of the vascular role of dystrophin, implies that vascular-targeted therapies are strong candidates for future investigation. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.